Compare Gilead Sciences, Inc. (GILD) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs RLX Technology Inc — how do they compare? Gilead Sciences, Inc. trades at $149.8 (market cap $182.40B), while RLX Technology Inc trades at $1.73 (market cap $2.10B). The key difference: Gilead Sciences, Inc. is far larger — about 86.9× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and RLX Technology Inc for 34 Days on average.
| GILD | RLX | |
|---|---|---|
Market Cap | $182.40B | $2.10B |
Volume | 4,469,821 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $2.57 |
52-Week Low | $116.74 | $1.68 |
Typical Hold Time | 111 Days | 34 Days |
Enterprise Value | $205.46B | $832.26M |
Dividend Yield | 2.23% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
RLX Technology trades at $1.73, showing no change in the latest session and recently hitting 52-week lows. The stock exhibits bearish technical signals with mixed fundamentals - revenue grew to $3.62B in 2025 with strong 21.87% net margins, but recent quarters show consistent earnings misses. Analyst coverage remains limited with a single hold rating, while cash flow trends show volatility with negative net cash flow in 2025.
RLX faces near-term headwinds from earnings underperformance and technical weakness, though valuation appears reasonable with P/E of 15.46 and P/B below 1.0. International expansion provides growth potential, but regulatory risks and margin compression require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
